Academic drug discovery: Current status and prospects

Expert Opinion on Drug Discovery

Volumn 10, Issue 9, 2015, Pages 937-944

  Everett, Jeremy R ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

academic; drug discovery; high throughput screening; molecular probes; pan assay interference compounds

Indexed keywords

ACADEMIC ACHIEVEMENT; BIOINFORMATICS; DRUG DEVELOPMENT; DRUG INDUSTRY; EXPERIENCE; FUTUROLOGY; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR PROBE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; COOPERATION; DRUG DESIGN; ORGANIZATION AND MANAGEMENT; UNIVERSITY;

COOPERATIVE BEHAVIOR; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; UNIVERSITIES;

EID: 84938910122     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1059816     Document Type: Review

References (56)

1. Kinch MS, Flath R. New drug discovery: extraordinary opportunities in an uncertain time. Drug Discov Today 2014. 10.1016/j.drudis.2014.12
2. Mullard A. 2014 fda drug approvals. Nat Rev Drug Discov 2015; 14 (2): 77-81
3. LaMattina JL. The impact of mergers on pharmaceutical RandD. Nature Reviews Drug Discovery 2011; 10 (8): 559-60
4. Comanor WS, Scherer FM. Mergers and innovation in the pharmaceutical industry. J Health Econ 2013; 32 (1): 106-13
5. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve randd productivity: The pharmaceutical industrys grand challenge. Nat Rev Drug Discov 2010; 9 (3): 203-14
6. Morgan P, Van der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase ii survival. Drug Discov Today 2012; 17 (9-10): 419-24
7. Arrowsmith J. Phase II failures: 2008-2010. Nat Rev Drug Discov 2011; 10 (5): 1
8. Rafols I, Hopkins MM, Hoekman J, et al. Big pharma, little science? A bibliometric perspective on big pharmas randd decline. Technol Forecast Soc Change 2014; 81: 22-38
9. Said M, Zerhouni E. The role of public-private partnerships in addressing the biomedical innovation challenge. Nature Reviews Drug Discovery 2014; 13 (11): 789-90
10. Goldman M. The innovative medicines initiative: A european response to the innovation challenge. Clin Pharmacol Ther 2012; 91 (3): 418-25
11. Chain E. Early years of the penicillin discovery. Trends Pharmacol Sci 1979; 1 (1): 6-11
12. Nayler JHC. Early discoveries in the penicillin series. Trends Biochem Sci 1991; 16 (5): 195-7
13. Nayler JHC. Structure-activity relationships in semi-synthetic penicillins. Proc R Soc Lond B Biol Sci 1971; 179 (1057): 357-67
14. Frearson J, Wyatt P. Drug discovery in academia: The third way? Expert Opin Drug Discov 2010; 5 (10): 909-19
15. Stevens AJ, Jensen JJ, Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011; 364 (6): 535-41
16. Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nat Rev Drug Discov 2011; 10 (6): 409-10
17. Slusher BS, Conn PJ, Frye S, et al. Bringing together the academic drug discovery community. Nat Rev Drug Discov 2013; 12 (11): 811-12
18. Academic drug discovery consortium (ad2c). 2015. Available from: http://addconsortium.Org/index.Php. [Last accessed 2 June 2015]
19. Society of laboratory automation and screening (slas). 2015. Available from: http://www.Slas.Org/resources/information/academic-screening-facilities/. [Last accessed 8 April 2015]
20. Huryn DM, Resnick LO, Wipf P. Contributions of academic laboratories to the discovery and development of chemical biology tools. J Med Chem 2013; 56 (18): 7161-76
21. Mullard A. European lead factory opens for business. Nat Rev Drug Discov 2013; 12 (3): 173-5
22. Besnard J, Jones PS, Hopkins AL, Pannifer AD. The joint european compound library: Boosting precompetitive research. Drug discov today 2015; 20 (2): 181-6
23. Orrling K. European lead factory status, personal communication. 2015
24. Frank R. Eu-openscreen-a european infrastructure of open screening platforms for chemical biology. ACS Chem Biol 2014; 9 (4): 853-4
25. Tralau-Stewart C, Low CMR, Marlin N. UK academic drug discovery. Nat Rev Drug Discov 2014; 13 (1): 15-16
26. Schultz Kirkegaard H, Valentin F. Academic drug discovery centres: The economic and organisational sustainability of an emerging model. Drug discov today 2014; 19 (11): 1699-710
27. Comley J. The current status of non-biopharma drug discovery. Drug Discovery World 2014; 62-9
28. Jorgensen WL. Challenges for academic drug discovery. Angew Chem Int Ed Engl 2012; 51 (47): 11680-4
29. Huryn DM. Drug discovery in an academic setting: Playing to the strengths. ACS Med Chem Lett 2013; 4 (3): 313-15
30. Dahlin JL, Inglese J, Walters MA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov 2015; 14: 279-94
31. Baell JB. Observations on screening-based research and some concerning trends in the literature. Future Med Chem 2010; 2 (10): 1529-46
32. Baell J, Walters MA. Chemical con artists foil drug discovery. Nature 2014; 513 (7519): 481-3
33. Bell AS, Bradley J, Everett JR, et al. Plate-based diversity subset screening: An efficient paradigm for high throughput screening of a large screening file. Mol Divers 2013; 17 (2): 319-35
34. Feng BY, Shoichet BK. Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem 2006; 49 (7): 2151-4
35. Bakken GA, Bell AS, Boehm M, et al. Shaping a screening file for maximal. Lead discovery efficiency and effectiveness: Elimination of molecular redundancy. J Chem Inf Model 2012; 52 (11): 2937-49
36. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010; 53 (7): 2719-40
37. Whitty A. Growing pains in academic drug discovery. Future Med Chem 2011; 3 (7): 797-801
38. Lane SJ, Eggleston DS, Brinded KA, et al. Defining and maintaining a high quality screening collection: The GSK experience. Drug Discov Today 2006; 11 (5-6): 267-72
39. Tang H, Walsh SP, Yan Y, et al. Discovery of selective small molecule romk inhibitors as potential new mechanism diuretics. ACS Med Chem Lett 2012; 3 (5): 367-72
40. Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine trail. Angew Chem Int Ed Engl 2014; 53 (26): 6628-31
41. Austin CP, Brady LS, Insel TR, Collins FS. NIH molecular libraries initiative. Science 2004; 306 (5699): 1138-9
42. Molecular libraries program. 2007. Available from: http://www.Mli.Nih.Gov/mli/. [Last accessed 3 June 2015]
43. Leinonen V, Rinne JO, Wong DF, et al. Diagnostic effectiveness of quantitative 18F flutemetamol pet imaging for detection of fibrillar amyloid beta using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta neuropathol commun 2014; 2: 46
44. Rpc1063 for rms. 2015. Available from: http://receptos.Com/clinical-pipeline/rpc1063-for-rms/. [Last accessed 3 June 2015]
45. Oprea TI, Bologa CG, Boyer S, et al. A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol 2009; 5 (7): 441-7
46. Hopkins A, Lanfear J, Lipinski C, Beeley L. Chemical tools for indications discovery. Annu Rep Med Chem 2005; 40: 339-48
47. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5 (8): 689-702
48. Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011; 8 (3-4): 61-9
49. Nair P. Drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs. Proc Natl Acad Sci USA 2013; 110 (7): 2430-2
50. Kaufman AC, Salazar SVH, Laura T, et al. Fyn inhibition rescues established memory and synapse loss in alzheimer mice. Ann Neurol 2015; 77 (6): 953-71
51. Repurposed experimental cancer drug restores brain function in mouse models of alzheimers disease: NIH, NIH web site. 2015. Available from: http://www.nih.gov/news/health/mar2015/ncats-31.htm
52. Bickle M. Systems drug discovery: A quantitative, objective approach for safer drug development. Expert Opin Drug Discov 2012; 7 (9): 757-9
53. Lindon J, Nicholson J, Holmes E, Everett J. Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson 2000; 12 (5): 289-320
54. Reily MD, Tymiak AA. Metabolomics in the pharmaceutical industry. Drug Discov Today: Technologies 2015
55. Bento AP, Gaulton A, Hersey A, et al. The ChEMBL bioactivity database: An update. Nucleic Acids Res 2014; 42 (D1): D1083-90
56. Willighagen EL, Waagmeester A, Spjuth O, et al. The ChEMBL database as linked open data. J Cheminform 2013; 5 (1): 23